Bright Minds Biosciences Inc.

NasdaqCM:DRUG Stock Report

Market Cap: US$807.5m

Bright Minds Biosciences Future Growth

Future criteria checks 2/6

Bright Minds Biosciences's earnings are forecast to decline at 23.5% per annum while its annual revenue is expected to grow at 68.8% per year. EPS is expected to decline by 16.7% per annum.

Key information

-23.5%

Earnings growth rate

-16.68%

EPS growth rate

Biotechs earnings growth25.4%
Revenue growth rate68.8%
Future return on equityn/a
Analyst coverage

Good

Last updated01 Jun 2026

Recent future growth updates

No updates

Recent updates

Seeking Alpha • Jan 07

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating

Summary Bright Minds Biosciences remains a "Strong Buy" after positive phase 2 data for BMB-101 in drug-resistant epilepsies. DRUG's BMB-101 achieved -73.1% and -63.3% median seizure reductions in Absence Epilepsy and DEE cohorts, respectively. Multiple 2026 catalysts include additional phase 2 data, phase 3 trial initiation, and a phase 2 PWS study for BMB-101. Recent $100M financing and ATM program extend the runway, but further capital raises may be needed as clinical programs advance. Read the full article on Seeking Alpha
Seeking Alpha • Apr 16

Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025

Summary We are initiating coverage of Bright Minds Biosciences with a Buy rating, as we believe the stock is undervalued. We see a key catalyst in the Phase 2 data readout for BMB-101, which is expected in Q2 2025. The company has a decent balance sheet, with roughly $40.3 million in cash. It may need to raise capital by mid-2026 or earlier as R&D expenses increase. A strategic partnership or acquisition could enhance value if the company's pipeline proves successful in clinic. Read the full article on Seeking Alpha
Seeking Alpha • Aug 18

Bright Minds says no material events fueled rally

After over 100% surge in its share price, Canadian biotech Bright Minds Biosciences (NASDAQ:DRUG) (OTCQB:BMBIF) announced Thursday that the company is unaware of any material events or undisclosed corporate actions that caused today’s rally. The company announced this in response to a request by the Investment Industry Regulatory Organization of Canada, which has sought its comments on its recent trading activity. DRUG, a pre-clinical biosciences company, added ~121% during regular trading on above-average volumes. About 119.5 company shares changed hands, compared to the 65-day average volume of ~58.3K. “The Company is not aware of any material, undisclosed corporate developments and has no material change in its business or affairs that has not been publicly disclosed that would account for the recent increase in volume or price,” Bright Minds (DRUG) said. DRUG shares have lost ~3.2% in post-market trading. Read Seeking Alpha’s “On the Move” section to monitor shares with the biggest moves.

Earnings and Revenue Growth Forecasts

NasdaqCM:DRUG - Analysts future estimates and past financials data (CAD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2028N/A-240-225-2506
9/30/202734-167-185-2037
9/30/2026N/A-63-73-697
3/31/2026N/A-27-20-20N/A
12/31/2025N/A-20-13-13N/A
9/30/2025N/A-12-9-9N/A
6/30/2025N/A-9-8-8N/A
3/31/2025N/A-3-4-4N/A
12/31/2024N/A-1-3-3N/A
9/30/2024N/A-3-2-2N/A
6/30/2024N/A-4-3-3N/A
3/31/2024N/A-5-4-4N/A
12/31/2023N/A-7-5-5N/A
9/30/2023N/A-7-7-7N/A
6/30/2023N/A-9-8-8N/A
3/31/2023N/A-10-9-9N/A
12/31/2022N/A-12-11-11N/A
9/30/2022N/A-15-14-14N/A
6/30/2022N/A-15-14-14N/A
3/31/2022N/A-16-14-14N/A
12/31/2021N/A-13-12-12N/A
9/30/2021N/A-9-7-7N/A
6/30/2021N/A-6-5-5N/A
3/31/2021N/A-3-2-2N/A
12/31/2020N/A-1-1-1N/A
9/30/2020N/A000N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DRUG is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DRUG is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DRUG is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DRUG's revenue (68.8% per year) is forecast to grow faster than the US market (11.9% per year).

High Growth Revenue: DRUG's revenue (68.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if DRUG's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/02 17:50
End of Day Share Price 2026/06/02 00:00
Earnings2026/03/31
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bright Minds Biosciences Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBaird
Charles MooreBaird
Joel BeattyBaird